NCT07159763: An ongoing trial by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This trial is ongoing. It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07159763 |
|---|---|
| Title | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 25, 2025 |
| Completion date | Jan. 31, 2027 |
| Required reporting date | Jan. 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |